Rhumatologie

Cost-Effectiveness of Two Therapeutic Regimens of Infliximab in Ankylosing Spondylitis: Economic Evaluation Within a Randomized Controlled Trial

Annals of the Rheumatic Diseases – Concise report – 2009 Bruno Fautrel, Mathilde Benhamou, Maxime Breban, Carine Roy, Christelle Lenoir, Gérard Trape, Alain Baleydier, Philippe Ravaud, Maxime Dougados

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Impact of disease activity for patients with axial spondyloarthritis
Rhumatologie

Impact of disease activity for patients with axial spondyloarthritis

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis
Rhumatologie

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France
Rhumatologie

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France